دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Identifying the Presence, Activity, and Status of Extraintestinal Manifestations of Inflammatory Bowel Disease Using Natural Language Processing of Clinical Notes
Ryan W Stidham, MD, MS, Deahan Yu, MHI, Xinyan Zhao, BS, Shrinivas Bishu, MD, Michael Rice, MD, Charlie Bourque, BS, Vinod V G Vydiswaran, PhD
doi : 10.1093/ibd/izac109
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 503–510
Extraintestinal manifestations (EIMs) occur commonly in inflammatory bowel disease (IBD), but population-level understanding of EIM behavior is difficult. We present a natural language processing (NLP) system designed to identify both the presence and status of EIMs using clinical notes from patients with IBD.
Prediction of Crohn’s Disease Stricturing Phenotype Using a NOD2-derived Genomic Biomarker
James J Ashton, PhD, Guo Cheng, PhD, Imogen S Stafford, MSci, Melina Kellermann, Eleanor G Seaby, BMBS, J R Fraser Cummings,, FRCP, Tracy A F Coelho, PhD, Akshay Batra, MD, Nadeem A Afzal, MD, R Mark Beattie, FRCPCH, Sarah Ennis, PhD
doi : 10.1093/ibd/izac205
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 511–521
Crohn’s disease (CD) is highly heterogenous and may be complicated by stricturing behavior. Personalized prediction of stricturing will inform management. We aimed to create a stricturing risk stratification model using genomic/clinical data.
Managing Inflammatory Bowel Disease in Pregnancy: Health Care Professionals’ Involvement, Knowledge, and Decision Making
Eleanor Liu, MBChB, MRCP, ESEGH, Robyn Laube, BMed MD MPH FRACP, Rupert W Leong, MBBS FRACP MD AGAF, Aileen Fraser, MSc, Christian Selinger, MD MSc FRCP, Jimmy K Limdi, MBBS FRCP FACG
doi : 10.1093/ibd/izac101
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 522–530
The management of pregnant women with inflammatory bowel disease (IBD) is complex. We aimed to assess health care professionals’ (HCPs) theoretical and applied knowledge of pregnancy-related IBD issues.
Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation
Jasmijn A M Sleutjes, MD, Jeanine E Roeters van Lennep, MD, PhD, C Janneke van der Woude, MD, PhD, Annemarie C de Vries, MD, PhD
doi : 10.1093/ibd/izac100
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 531–538
Dyslipidemia may be an important modifiable risk factor contributing to the increased cardiovascular risk in inflammatory bowel disease (IBD). The lipid metabolism is subject to both systemic inflammation and drug therapy; however, it is unclear if this effect is drug-class dependent. Our aim was to assess lipid changes after IBD induction therapy and evaluate associated factors with a particular focus on drug class and disease activity.
Early Biological Therapy in Operated Crohn’s Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience
Ferdinando D’Amico, MD, Olga Tasopoulou, MD, Gionata Fiorino, MD, PhD, Alessandra Zilli, MD, Federica Furfaro, MD, Mariangela Allocca, MD, PhD, Pierpaolo Sileri, MD, Antonino Spinelli, MD, PhD, Laurent Peyrin-Biroulet, MD, PhD, Silvio Danese, MD, PhD
doi : 10.1093/ibd/izac110
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 539–547
Two-thirds of Crohn’s disease (CD) patients require surgery during their disease course. However, surgery is not curative, and endoscopic recurrence is observed in up to 90% of cases. Our aim was to investigate the impact of postoperative biological therapy on the incidence of endoscopic recurrence and long-term outcomes in CD patients.
Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn’s Disease: A Multicenter Observational Study
Jihye Park, MD, PhD, Jaeyoung Chun, MD, PhD, Hyuk Yoon, MD, PhD, Jae Hee Cheon, MD, PhD
doi : 10.1093/ibd/izac105
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 548–554
Ustekinumab was recently approved for the treatment of moderate to severe Crohn’s disease (CD). Although the ustekinumab Clinical Decision Support Tool (UST-CDST) was able to predict ustekinumab responsiveness in a clinical trial, it is not clear whether UST-CDST can also predict a future clinical relapse following ustekinumab therapy in the real-life setting.
A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn’s Disease
Ariela K Holmer, MD, Brigid S Boland, MD, Siddharth Singh, MD, MS, Jennifer Neill, Helen Le, Ara Miralles, NP, Angelina E Collins, NP, William J Sandborn, MD, Parambir S Dulai, MD
doi : 10.1093/ibd/izac117
The Endoscopic Healing Index (EHI) is a serum biomarker panel that can predict endoscopic inflammation in Crohn’s disease (CD).
David Against Goliath: Direct Comparison of Handheld Bowel Sonography and Magnetic Resonance Enterography for Diagnosis of Crohn’s Disease
Antonio Rispo, MD, PhD, Roberto de Sire, MD, Pier Paolo Mainenti, MD, Nicola Imperatore, MD, PhD, Anna Testa, MD, PhD, Simone Maurea, MD, Simona Ricciolino, MD, Olga Maria Nardone, MD, PhD, Oriana Olmo, MD, Fabiana Castiglione, MD
doi : 10.1093/ibd/izac116
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 563–569
Diagnosis of Crohn’s disease (CD) requires ileo-colonoscopy (IC) and cross-sectional evaluation. Recently, “echoscopy� has been used effectively in several settings, although data about its use for CD diagnosis are still limited. Our aim was to evaluate the diagnostic accuracy of handheld bowel sonography (HHBS) in comparison with magnetic resonance enterography (MRE) for CD diagnosis.
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
Millie D Long, MD, MPH, Anita Afzali, MD, MPH, Monika Fischer, MD, David Hudesman, MD, Maisa Abdalla, MD, MPH, Robert McCabe, MD, Benjamin L Cohen, MD, Ryan C Ungaro, MD, MS, Will Harlan, MD, John Hanson, MD, Gauree Konijeti, MD, MPH, Steven Polyak, MD, Timothy Ritter, MD, Bruce Salzberg, MD, Jennifer Seminerio, MD, Emily English, BA, MSW, Xian Zhang, PhD, Puza P Sharma, MD, PhD, Hans H Herfarth, MD, PhD
doi : 10.1093/ibd/izac121
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 570–578
Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe the onset of tofacitinib efficacy during induction therapy in a real-world study.
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study
Anthony Buisson, MD, PhD, Mélanie Serrero, MD, Laurie Orsat, MSc, Stéphane Nancey, MD, PhD, Pauline Rivière, MD, Romain Altwegg, MD, Laurent Peyrin-Biroulet, MD, PhD, Maria Nachury, MD, Xavier Hébuterne, MD, PhD, Cyrielle Gilletta, MD, Mathurin Flamant, MD, Stéphanie Viennot, MD, Guillaume Bouguen, MD, PhD, Aurélien Amiot, MD, PhD, Stéphane Mathieu, MD, Lucine Vuitton, MD, PhD, Laurianne Plastaras, MD, Arnaud Bourreille, MD, PhD, Ludovic Caillo, MD, Félix Goutorbe, MD, Guillaume Pineton De Chambrun, MD, Alain Attar, MD, Xavier Roblin, MD, PhD, Bruno Pereira, PhD, Mathurin Fumery, MD, PhD
doi : 10.1093/ibd/izac119
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 579–588
Owing to growing number of therapeutic options with similar efficacy and safety, we compared the acceptability of therapeutic maintenance regimens in inflammatory bowel disease (IBD).
Aberrant Mucin Expression Profiles Associate With Pediatric Inflammatory Bowel Disease Presentation and Activity
Tom Breugelmans, MSc, Wout Arras, MSc, Lauren-Emma Boen, MD, Eliah Borms, MD, Lisa Kamperdijk, MD, Joris De Man, MSc, Els Van de Vijver, MD, Ann Van Gils, MD, Benedicte Y De Winter, PhD, Nicolette Moes, PhD, Annemieke Smet, PhD
doi : 10.1093/ibd/izac217
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 589–601
Intestinal mucosal healing is nowadays preferred as the therapeutic endpoint in inflammatory bowel disease (IBD), but objective measurements at the molecular level are lacking. Because dysregulated mucin expression is suggested to be involved in mucosal barrier dysfunction in IBD, we investigated mucin expression in association with barrier mediators and clinical characteristics in colonic tissue of a pediatric IBD population.
Hypoxic ASCs-derived Exosomes Attenuate Colitis by Regulating Macrophage Polarization via miR-216a-5p/HMGB1 Axis
Wenwei Qian, PhD, Liangyu Huang, PhD, Yihan Xu, MD, Wen Lu, MD, Weiwei Wen, MD, Zhen Guo, MD, PhD, Weiming Zhu, MD, PhD, Yi Li, MD, PhD
doi : 10.1093/ibd/izac225
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 602–619
Exosomes derived from mesenchymal stem cells have shown therapeutic effects for colitis. As a more clinically accessible resource, the therapeutic potential of exosomes from adipose-derived stem cells (ASCs) has not been fully elucidated, and whether hypoxia precondition could improve the therapeutic effect of ASC-derived exosomes in colitis remains elusive.
Vitamin D3 and Lactobacillus rhamnosus GG/p40 Synergize to Protect Mice From Colitis by Promoting Vitamin D Receptor Expression and Epithelial Proliferation
Dan Chen, MD, Hao Tang, MD, Yue Li, MD, Hong Yang, MD, Hongying Wang, PhD, Bei Tan, MD, Jiaming Qian, MD
doi : 10.1093/ibd/izac238
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 620–632
While vitamin D (VitD) levels are negatively correlated with inflammatory bowel disease (IBD) activity, VitD supplementation does not reduce IBD severity. The probiotic Lactobacillus rhamnosus GG (LGG), which secretes p40, can upregulate colonic VitD receptor (VDR) expression. We therefore evaluated synergy between VitD3 and LGG/p40 in the treatment of mouse colitis.
The Role of Appendicectomy in Ulcerative Colitis: Systematic Review and Meta-Analysis
Silje Welsh, MSc, Zihao Sam, MSc, John Paul Seenan, MD, Gary A Nicholson, MD
doi : 10.1093/ibd/izac127
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 633–646
This updated systematic review and meta-analysis investigates the putative role of the appendix in ulcerative colitis as a therapeutic target.
Deletion of Smad7 Ameliorates Intestinal Inflammation and Contributes to Fibrosis
Cordelia Schuler, Federica Foti, MSc, Leonie Perren, BSc, Céline Mamie, MSc, Bruce Weder, PhD, Michelle Stokmaier, Cheryl de Vallière, PhD, Rainer Heuchel, PhD, Pedro A Ruiz, PhD, Gerhard Rogler, MD, PhD, Martin Hausmann, PhD
doi : 10.1093/ibd/izac221
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 647–660
Patients suffering from inflammatory bowel diseases (IBDs) express increased mucosal levels of transforming growth factor (TGF)-β compared with non-IBD controls. SMAD7 negatively regulates TGF-β signaling. An earlier study aiming to target Smad7 showed a lack of clinical benefit. It remains unknown whether inhibition of SMAD7 is beneficial in specific settings of IBD. We evaluated the effect of Smad7 deficiency on inflammation, fibrogenesis, and wound healing.
New Pneumococcal Vaccines for Prevention of Invasive Pneumococcal Disease in Adult Patients With Inflammatory Bowel Disease
Sheena Crosby, PharmD, BCGP, Michael J Schuh, PharmD, MBA, FAPhA, Michelle Becker, PharmD, BCACP, Marina Ivanov, PharmD, BCPS, BCACP, Freddy Caldera, DO, MS, Francis A Farraye, MD, MSc
doi : 10.1093/ibd/izac150
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 661–664
Patients with inflammatory bowel disease (IBD) are at a high risk of developing invasive pneumococcal infection both before and after they are diagnosed. The Advisory Committee on Immunization Practices now endorses use of 2 new pneumococcal conjugate vaccines, PCV15 (Vaxneuvance) and PCV20 (Prevnar 20), for patients who have never received a pneumococcal conjugate vaccine or those with unknown vaccination history
The Value of a Dedicated IBD Flare Clinic to Effectively Manage Exacerbations of Inflammatory Bowel Disease: The Edinburgh IBD Unit
Rebecca K Grant, MBChB, William M Brindle, MBChB, Ian D R Arnott, MBChB
doi : 10.1093/ibd/izac159
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 665–668
The Endoscopic Healing Index in Crohn’s Disease: A Serum Proteomic Biomarker for Monitoring Disease Activity
Nurulamin M Noor, MRCP, James C Lee, PhD
doi : 10.1093/ibd/izac126
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 669–671
Challenges and Opportunities for Advancing Research and Improving Care for Sexual and Gender Minorities With Inflammatory Bowel Disease
Taylor Boyd, MMSc, Sonia Friedman, MD
doi : 10.1093/ibd/izac229
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 672–674
Reply: Frail Phenotype in Patients With Inflammatory Bowel Disease
Silvia Salvatori, MD, Giovanni Monteleone, MD, PhD
doi : 10.1093/ibd/izad015
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Page e13
Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients
Cong Dai, MD, PhD, Yu-Hong Huang, MD, PhD
doi : 10.1093/ibd/izad025
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Page e14
Reply: Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients
Marco Valvano, MD, Antonio Vinci, MD, Giovanni Latella, MD
doi : 10.1093/ibd/izad028
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages e15–e16
